Importantly, clinical trials are now ongoing in which rhTrx1 is being administered to patients with atopic dermatitis and trans-tracheal inhalation experiment with rhTrx1 are being performed; Trx1 is showing good efficacy with no major side effects (unpublished data). This evidence concerns the gene TXN and atopic eczema.